Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEOGENOMICS INCNEO · Entity 2096 | Chief Sustainability/Risk Ofcr | January 11, 2022 | January 12, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEOGENOMICS INC
Report date January 11, 2022 · Filed January 12, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 49,361 |
Reported balance
After 2022-01-11 transaction · row 1
1 source rowRow 1 · 2022-01-11 · Exercise / conversion · Acquired 2,100 · Balance 49,361 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.07 · Expires 2022-10-18 | Direct | 17,900 |
Reported balance
After 2022-01-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-01-11 · Exercise / conversion · Disposed 2,100 · Balance 17,900 F1: On October 17, 2017, Ms. McKenzie was granted 25,000 stock options. These options vested ratably over the first three anniversary dates of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.03 · Expires 2023-02-26 | Direct | 40,000 |
Reported balance
Holding disclosure · report date 2022-01-11 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 40,000 F2: On February 26, 2018, Ms. McKenzie was granted 48,000 stock options. These options vested ratably over the first three anniversary dates of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.60 · Expires 2024-03-01 | Direct | 13,894 |
Reported balance
Holding disclosure · report date 2022-01-11 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 13,894 F3: On March 1, 2019, Ms. McKenzie was granted 13,894 stock options. These options vest ratably over the first four anniversary dates of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.33 · Expires 2027-03-02 | Direct | 37,514 |
Reported balance
Holding disclosure · report date 2022-01-11 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 37,514 F4: On March 2, 2020, Ms. McKenzie was granted 37,514 stock options. These options vest ratably over the first four anniversary dates of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $53.17 · Expires 2028-03-02 | Direct | 35,171 |
Reported balance
Holding disclosure · report date 2022-01-11 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 35,171 F5: On March 2, 2021, Ms. McKenzie was granted 35,171 stock options. These options vest ratably over the first four anniversary dates of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: On October 17, 2017, Ms. McKenzie was granted 25,000 stock options. These options vested ratably over the first three anniversary dates of the grant date.
F2: On February 26, 2018, Ms. McKenzie was granted 48,000 stock options. These options vested ratably over the first three anniversary dates of the grant date.
F3: On March 1, 2019, Ms. McKenzie was granted 13,894 stock options. These options vest ratably over the first four anniversary dates of the grant date.
F4: On March 2, 2020, Ms. McKenzie was granted 37,514 stock options. These options vest ratably over the first four anniversary dates of the grant date.
F5: On March 2, 2021, Ms. McKenzie was granted 35,171 stock options. These options vest ratably over the first four anniversary dates of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 11, 2022 Filed Jan 12, 2022 23:50 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,100 | $0.00 Strike: $9.07 | $0.00 |
DisclosureSEC source: 0001077183-22-000002 · wf-form4_164203142741919.xml · derivative · entry 2 McKenzie Kathryn B · CIK 0001720001 · Chief Sustainability/Risk Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,900 Underlying: Common Stock · 2,100 shares Expires 2022-10-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: On October 17, 2017, Ms. McKenzie was granted 25,000 stock options. These options vested ratably over the first three anniversary dates of the grant date. Read SEC document |
| January 11, 2022 Filed Jan 12, 2022 23:50 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 2,100 | $9.07 | $19,047.00 |
DisclosureSEC source: 0001077183-22-000002 · wf-form4_164203142741919.xml · nonDerivative · entry 1 McKenzie Kathryn B · CIK 0001720001 · Chief Sustainability/Risk Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,361 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 30, 2021 Filed Dec 30, 2021 23:04 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantCommon Stock | 30,572 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-21-000276 · wf-form4_164090544806977.xml · nonDerivative · entry 1 McKenzie Kathryn B · CIK 0001720001 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,261 F1 · kind: On December 30, 2021, Ms. McKenzie was granted 30,572 restricted stock awards. These awards vest ratably over three years with the first tranche vesting on December 31, 2022. Read SEC document |
| December 22, 2021 Filed Dec 23, 2021 22:25 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $9.07 | $0.00 |
DisclosureSEC source: 0001077183-21-000260 · wf-form4_164029831264611.xml · derivative · entry 3 McKenzie Kathryn B · CIK 0001720001 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 5,000 shares Expires 2022-10-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · derivative.exercise_date: On October 17, 2017, Ms. McKenzie was granted 25,000 stock options. These options vested ratably over the first three anniversary dates of the grant date Read SEC document |
| December 22, 2021 Filed Dec 23, 2021 22:25 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 5,000 | $9.07 | $45,350.00 |
DisclosureSEC source: 0001077183-21-000260 · wf-form4_164029831264611.xml · nonDerivative · entry 2 McKenzie Kathryn B · CIK 0001720001 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,689 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| December 21, 2021 Filed Dec 23, 2021 22:25 UTC | NEOGENOMICS INC NEO · Entity 2096 | SaleCommon Stock | 1,846 | $35.00 | $64,610.00 |
DisclosureSEC source: 0001077183-21-000260 · wf-form4_164029831264611.xml · nonDerivative · entry 1 McKenzie Kathryn B · CIK 0001720001 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,689 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 01:19 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 35,171 | $53.17 Strike: $53.17 | $1,870,042.07 |
DisclosureSEC source: 0001077183-21-000087 · wf-form4_161482075291006.xml · derivative · entry 8 McKenzie Kathryn B · CIK 0001720001 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,171 Underlying: Common Stock · 35,171 shares Expires 2028-03-02 F7 · derivative.exercise_date: On March 2, 2021, Ms. McKenzie was granted 35,171 stock options. These options vest ratably over the first four anniversary dates of the grant date. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 01:19 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantCommon Stock | 6,207 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-21-000087 · wf-form4_161482075291006.xml · nonDerivative · entry 3 McKenzie Kathryn B · CIK 0001720001 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,535 Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 01:19 UTC | NEOGENOMICS INC NEO · Entity 2096 | Tax withholdingCommon Stock | 432 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-21-000087 · wf-form4_161482075291006.xml · nonDerivative · entry 2 McKenzie Kathryn B · CIK 0001720001 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,328 F2 · shares: Shares surrendered to NeoGenomics Inc. for retirement to satisfy the tax obligations in connection with the March 2, 2021 vesting of restricted stock. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:19 UTC | NEOGENOMICS INC NEO · Entity 2096 | Tax withholdingCommon Stock | 169 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-21-000087 · wf-form4_161482075291006.xml · nonDerivative · entry 1 McKenzie Kathryn B · CIK 0001720001 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,760 F1 · shares: Shares surrendered to NeoGenomics Inc. for retirement to satisfy the tax obligations in connection with the March 1, 2021 vesting of restricted stock. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 01:00 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantCommon Stock · Derivative | 37,514 | $28.33 Strike: $28.33 | $1,062,771.62 |
DisclosureSEC source: 0001077183-20-000030 · wf-form4_158328361900393.xml · derivative · entry 6 McKenzie Kathryn B · CIK 0001720001 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,514 Underlying: Common Stock · 37,514 shares Expires 2027-03-02 F5 · derivative.exercise_date: On March 2, 2020, Ms. McKenzie was granted 37,514 stock options. These options vest ratably over the first four anniversary dates of the grant date. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 01:00 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantCommon Stock | 5,824 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-20-000030 · wf-form4_158328361900393.xml · nonDerivative · entry 2 McKenzie Kathryn B · CIK 0001720001 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,929 Read SEC document |
| March 01, 2020 Filed Mar 4, 2020 01:00 UTC | NEOGENOMICS INC NEO · Entity 2096 | Tax withholdingCommon Stock | 168 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-20-000030 · wf-form4_158328361900393.xml · nonDerivative · entry 1 McKenzie Kathryn B · CIK 0001720001 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,105 F1 · shares: Shares withheld by NeoGenomics Inc. to satisfy the tax obligations in connection with the March 1, 2020 vesting of restricted stock. Read SEC document |
| December 10, 2019 Filed Dec 13, 2019 00:28 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $8.03 | $0.00 |
DisclosureSEC source: 0001077183-19-000230 · wf-form4_157619689019440.xml · derivative · entry 3 McKenzie Kathryn B · CIK 0001720001 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 8,000 shares Expires 2023-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: On February 26, 2018, Ms. McKenzie was granted an option to purchase 48,000 shares of NeoGenomics, Inc. common stock. The options vest ratably over the first three anniversary dates of the grant date. Read SEC document |
| December 10, 2019 Filed Dec 13, 2019 00:28 UTC | NEOGENOMICS INC NEO · Entity 2096 | SaleCommon Stock | 8,000 | $26.37 | $210,960.00 |
DisclosureSEC source: 0001077183-19-000230 · wf-form4_157619689019440.xml · nonDerivative · entry 2 McKenzie Kathryn B · CIK 0001720001 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,273 Read SEC document |
| December 10, 2019 Filed Dec 13, 2019 00:28 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 8,000 | $8.03 | $64,240.00 |
DisclosureSEC source: 0001077183-19-000230 · wf-form4_157619689019440.xml · nonDerivative · entry 1 McKenzie Kathryn B · CIK 0001720001 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,273 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 21:59 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 13,894 | $19.60 Strike: $19.60 | $272,322.40 |
DisclosureSEC source: 0001077183-19-000029 · wf-form4_155182313355816.xml · derivative · entry 2 McKenzie Kathryn B · CIK 0001720001 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,894 Underlying: Common Stock · 13,894 shares Expires 2024-03-01 F1 · derivative.exercise_date: On March 1, 2019, Ms. McKenzie was granted an option to purchase 13,894 shares of NeoGenomics, Inc. common stock. The options vest ratably over the first four anniversary dates of the grant date. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 21:59 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantCommon Stock | 2,273 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-19-000029 · wf-form4_155182313355816.xml · nonDerivative · entry 1 McKenzie Kathryn B · CIK 0001720001 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,273 Read SEC document |
| February 26, 2018 Filed Feb 28, 2018 23:59 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 48,000 | $8.03 Strike: $8.03 | $385,440.00 |
DisclosureSEC source: 0001209191-18-014684 · doc4.xml · derivative · entry 2 McKenzie Kathryn B · CIK 0001720001 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,000 Underlying: Common Stock · 48,000 shares Expires 2023-02-26 F2 · derivative.exercise_date: On February 26, 2018, Ms. McKenzie was granted an option to purchase 48,000 shares of NeoGenomics, Inc. common stock. The options vest ratably over the first three anniversary dates of the grant date. Read SEC document |
| October 18, 2017 Filed Oct 20, 2017 20:03 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $9.07 Strike: $9.07 | $226,750.00 |
DisclosureSEC source: 0001209191-17-057606 · doc4.xml · derivative · entry 1 McKenzie Kathryn B · CIK 0001720001 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2022-10-18 F1 · derivative.exercise_date: On October 18, 2017, Ms. McKenzie was granted an option to purchase 25,000 shares of NeoGenomics, Inc. common stock. The options vest ratably over the first three anniversary dates of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.